#NEWS: We have acquired Nerio Therapeutics. Why? Their knowledge will help us to fight cancer by activating our own immune system. Learn more on why we have added their small molecule checkpoint inhibitor to our oncology pipeline: https://lnkd.in/e9i3SdqY #Cancer #ImmunoOncology #ResearchAndDevelopment
🚀 Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of Nerio Therapeutics Inc. (“Nerio”) for a total of up to 1.3 billion USD. #BOLD #IMPACT #INVESTING
Great news! We hope this helps propel medical advancements even further.
Exciting news! 👏
Exciting news! Integrating Nerio Therapeutics' checkpoint inhibitor could be a game-changer in enhancing immune system activation for cancer treatment. Looking forward to seeing the impact on our oncology pipeline! #Cancer #ImmunoOncology #ResearchAndDevelopment
I am very proud to be part of this company! Cancer immunology is really a very good approach to fight against cancer! Go ahead with that, please!
Exciting news! 🌟 Acquiring Nerio Therapeutics is a significant step forward in our fight against cancer. 😃
Great to see that another Viva BioInnovator portfolio company is feeding the pharmaceutical drug R&D pipeline. Congratulations to Sandy Madigan, Sergio Duron and the whole Nerio team at Avalon BioVentures! It is my great honor to be part of this journey.
Keep growing!
Fantastic!! Working toward improving plus extending lives for people with cancer!1
Associate Director Oncology Strategic Accounts at Boehringer Ingelheim
3moExcited to see another example of my company’s commitment to oncology!